Panther® Scalable Solutions

Scalable growth today and tomorrow

Panther Scalable Solutions allows you to expand your testing menu while adding on flexibility, capacity and walkaway time.

Choose

Select from a broad menu of Aptima® and Panther Fusion® assays to run on scalable automation that meets your needs today and supports future growth.

Build

The Panther system serves as the foundation of our automation with the option to add on: the Panther Fusion module, Panther Plus, Panther Link and Panther Trax.

Grow

Panther Scalable Solutions provides an economical and scalable path to your lab’s growth today and into the future.

Consolidate your assay menu

The Aptima and Panther Fusion assays help guide patient care and enable early detection. With a menu and pipeline of world-class assays you can consolidate your molecular testing today and meet your lab’s growing needs tomorrow.

21

Assays Available

10

1

Scalable Platform

Assay Menu

Women's Health

CT/NG

Mycoplasma genitalium

Trichomonas vaginalis

Bacterial vaginosis

Candida vaginitis/
Trichomonas vaginalis

Zika Virus*

M. gen macrolide resistance^†

Chlamydia trachomatis^†

Neisseria gonorrhoeae^†

Infectious Disease

SARS-CoV-2/Flu A/B/RSV

GI Bacterial^†

GI Extended Bacterial^†

GI Viral^†

GI Parasite^†

EBV^†

BKV^†

C. Difficile^†

What will you build?

Panther® System

The foundation for assay consolidation, future scalability and growth
Add the Panther system to your lab and the capability to consolidate menu on a fully automated system, load samples in any order at any time, eliminate batch constraints and decrease turnaround time.

Panther Fusion® System

Flexibility, capacity and expanded menu, plus the ability to run laboratory developed tests.

Add on the power to run real-time PCR, TMA and RT-TMA assays on a single, fully automated platform. The Panther Fusion® module enables you to consolidate testing, increase walkaway time and enhance flexibility.

Panther® Plus

Increased capacity, walkaway time and throughput in 24 hours

Add on capacity with the MTU expansion module and gain the ability to plumb liquid waste and continuously dispose of fluids/wastes.

Panther® Link

Virtually connected Panther systems share information and monitor from a centralized dashboard

Add on freedom by virtually connecting multiple Panther instruments, giving you the ability to share inventories, reagents and results while monitoring your entire fleet from a core location.

Panther® Trax

Physically connected Panther systems grow testing volumes without increasing staff

Add on a track system that enables sample to storage automation, giving your molecular lab the potential to grow as you grow.

Find Support

All Other Requests

* The Aptima SARS-CoV-2, Aptima Zika Virus, Aptima SARS-CoV-2/Flu and Panther Fusion SARS-CoV-2 assays have not been FDA cleared or approved: These tests have been authorized by FDA under an EUA for use by authorized laboratories; The Aptima and Panther Fusion SARS-CoV-2 assays have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; The Aptima Zika Virus assay has been authorized only for the detection of nucleic acid from Zika virus, not for any other viruses or pathogens; The Aptima SARS-CoV-2/Flu assay has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A virus, influenza B virus, and not for any other viruses or pathogens. The Aptima SARS-CoV-2, Panther Fusion SARS-CoV-2, and Aptima SARS-CoV-2/Flu assays are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. The Aptima Zika assay is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

† In Development and not for sale